Schedule 13G ownership disclosure

Aligos Therapeutics Inc

Common Stock, par value, $0.0001 per share · CUSIP: 01626L204

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Alyeska Investment Group, L.P.

    Shares: 530,000.00 · Class: 9.99%

  • Alyeska Fund GP, LLC

    Shares: 530,000.00 · Class: 9.99%

  • Anand Parekh

    Shares: 530,000.00 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001172661-25-002361
Form type
SCHEDULE 13G
Filer
Aligos Therapeutics, Inc.
CIK
CIK 1799448
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub